NextCell Pharma publishes Interim Report 2 2021/2022

April 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website:https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Second quarter (2021-12-01 until 2022-02-28)

● Operating income amounted to 1 840 (1 008) TSEK.
● Operating result amounted to -10 212 (-8 149) TSEK.
● Earnings per share* amounted to -0,30 (-0,27) SEK.
● Cash and bank amounted to 118 170 (148 936) TSEK.
● Solidity** amounted to 94,3 (96,8) %.

First half-year (2021-09-01 till 2022-02-28)

● Operating income amounted to 3 187 (2 141) TSEK.
● Operating result amounted to -16 906 (-13 678) TSEK.
● Earnings per share* amounted to -0,22 (-0,51) SEK.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523 (29,717,519) shares. Average number of shares for the first half year 2021/2022: 34,379,523 (26,540,470) shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (33,712,857) shares. **Solidity: Own capital's share of the sheet total

‍

Significant events in the second quarter

● NextCell announced in December that it has entered into a cooperation agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects in support of everyone living with and around T1D. Together we want to spread hope fortype 1 diabetes research and make NextCell's clinical trials visible.
● NextCell announced in January that the company's CEO, Mathias Svahn, had been invited to give a presentation about the company's journey in cell therapy at the Advanced Therapy Week in Miami, USA at the end of January.
● NextCell announced in early February that the company had increased its involvement in FamiCordTx, a joint venture in cell and gene therapy, in a new share issue by approximately 160 kEUR.
● NextCell announced in mid-February that a Pediatric Diabetes Study is underway and that the company is contributing ProTrans and placebo.
● NextCell announced at the end of February that the Canadian probation for ProTrans in COVID-19 will be expanded to a multicenter study
● NextCell announced at the end of October that the clinical trial ProTrans19+SE can begin recruiting patients in the mean dose group. Three patients treated with a low dose of ProTrans have been clinically evaluated and the data have been reviewed by the Safety Committee, which now allows continued medium-dose treatment of ProTrans for severe pneumonia caused by COVID-19.

Significant events after the reporting period

● NextCell announced in early April that the stem cell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in cellovia's biobank, suffers from a serious blood disorderto be treated with stem cells at the Hematology Department at Rigshospitalet.
● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-04-2022 08:00 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO)

Download attachment Read full press release on Cision (external link)

2018-02-16

NextCell Pharma files patent application

NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans. The selection algorithm is based on multiple functional assays used to identify and select cells and donors with specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple donors. The pooling process supports the production of large batches. The combination

Read more Read more

2018-01-31

NextCell Pharma changes ticker to NXTCL

NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL. Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications and company branding. The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will remain the same. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation.

Read more Read more

2018-01-24

First diabetes patient treated with ProTrans stem cells

NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a maximum of two years. The clinical trial started on November 28th, 2017 and after clinical assessment and baseline data collection, the first patient has now been treated (first-in-human) with ProTrans stem cells. The first part of the study is a three-step dose escalation with three patients in each

Read more Read more

2017-11-29

NextCell Pharma initiates stem cell trial for type 1-diabetes with ProTrans

NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving ProTrans stem cell treatment. Patients with type 1-diabetes being 18-40 years who received their diagnosis no later than 2 years ago and still have some insulin production are candidates for participation in the trial. NextCell Pharma has reached a new level as a company. I would like to thank all the

Read more Read more

2017-11-14

Today Nextcell Pharma publishes its annual report 2016-2017

NextCell Pharma AB (publ) hereby publishes the annual report for the financial year 2016/2017. The annual report is attached to this press release and can be downloaded from the company's website www.nextcellpharma.com

Read more Read more

2017-10-31

NextCell Pharma updates on its situation in its fourth quarter report

NextCell Pharma AB ("NEXTCL", "NextCell") today releases its Q4 / year-end report (June 1st - August 31st / September 1st - August 31st). This is the first quarterly report since the listing on Aktietorget. The company reports a loss of SEK -4,757,996 in its fourth quarter and a loss of SEK -13,245,206 for the entire financial year. The remaining cash at August 31st was approximately 16 MSEK. The perhaps most important event during the fourth quarter was the listing on Aktietorget on July 13th and the associated listing issue, which was subscribed to approximately 18 MSEK, corresponding to

Read more Read more

2017-10-17

NextCell Pharma's stem cell study in Type 1 Diabetes gets green light from the Medical Products Agency

NextCell Pharma AB ("NextCell") today announces that the Swedish Medical Products Agency has granted permission to conduct the clinical trial investigating the drug candidate ProTrans. For more information regarding the clinical trial, please see press release from 15th of September. This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on October 17th, 2017.

Read more Read more

2017-10-11

Family saving of stem cells at Underbara Barn held atStockholm International Fair and Congresses Centre,13-15 October, 2017

For the third consecutive year, Cellaviva will exhibit at the Underbara Barn Fair to meet and inform its (prospective) customers. The fair is targeted at future parents and those with young children. Representatives from the company will inform visitors about the family saving of stem cells from the umbilical cord. Cellaviva is Sweden's first and only biobank for family-saving of stem cells and is owned by the stem cell company NextCell Pharma AB (NEXTCL). The applications for stem cell therapy are rapidly growing in modern medicine. Cells from family members are preferred for the treatment

Read more Read more